Key result
Administration of the KATP channel blocker 5-hydroxydecanoate significantly attenuated ischemia-induced action potential shortening and eliminated the difference in shortening between the epicardium and endocardium.
Why the study?
Does 5-hydroxydecanoate (a KATP channel blocker) prevent the differential shortening of epicardial and endocardial monophasic action potentials during regional ischemia in an open-chest dog model?
Does 5-hydroxydecanoate (a KATP channel blocker) prevent the differential shortening of epicardial and endocardial monophasic action potentials during regional ischemia in an open-chest dog model?
p-value: p=<0.05
KATP channel activation contributes to early action potential shortening during regional ischemia, with a lower activation threshold in the epicardium, potentially increasing transmural repolarization heterogeneity and arrhythmogenesis.
Should not inform clinical ischemia management; extends evidence for KATP-mediated transmural APD heterogeneity in animal models.
No takes yet. Share an insight, caveat, or question.
Miyoshi et al. (1994) studied Regional myocardial ischemia (n=20). 5-hydroxydecanoate (5-HD) vs. Control ischemia (prior occlusion without 5-HD) was evaluated on Shortening velocity of monophasic action potential duration (APD90) during early ischemia (p=<0.05). Administration of the KATP channel blocker 5-hydroxydecanoate significantly attenuated ischemia-induced action potential shortening and eliminated the difference in shortening between the epicardium and endocardium.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: